Home / Intelligence

Type
  • All
  • Blog
  • Briefs
  • Case Studies
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Featured Topic
  • All
  • AIML
  • Analytics
  • APAC
  • Benchmarking
  • Biosimilars
  • CAR-T
  • Cell and Gene Therapy
  • Commercial Operations
  • Competitive Intelligence
  • Contract Analytics
  • Corporate Strategy
  • COVID-19
  • Customer Engagement
  • Data Management
  • Digital Therapeutics
  • Diversity
  • Emerging Life Sciences
  • Europe
  • Evidence Strategy (HEOR)
  • Field Force
  • Forecasting
  • Generative AI
  • Incentive Compensation
  • Inflation Reduction Act
  • Insights
  • International
  • LatAm
  • Launch and Brand Excellence
  • Learning and Development
  • Market Research
  • Marketing
  • Medical Affairs
  • MedTech
  • New Product Planning
  • NRDL
  • Omnichannel
  • Oncology
  • Patient Centricity
  • Patient Finding
  • Patient Services
  • Performance Tracking
  • Pricing and Access
  • Product Demos
  • Rare Disease
  • Real-World Evidence
  • Scientific Publications
  • Sustainability
  • Talent Acquisition and Retention
  • United States
  • Value Communication
Search

Webinars

Navigating the Early Asset Evaluation Journey with Confidence

February 25, 2025 | 1:00 - 1:45 PM ET

There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle. Join a team of cross-functional experts for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives.

Sign Up Now

Scientific Publications

Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis

Chronic Graft-Versus-Host Disease (cGVHD) is a complication of hematopoietic cell transplantation (HCT). While the clinical outcomes of cGVHD are well documented, few studies have assessed its treatment practices in the real-world. The objectives of this study are to quantify the prevalence of cGVHD, to examine provider prescribing patterns, and to evaluate the healthcare cost and resource utilization (HCRU) in a real-world US cGVHD population. Authors Carlos Bachier, Sanjay Aggarwal, Kalin Hennegan, Andrew Milgroom, Kevin Francis, Marcello Rotta Journal Blood; American…

Read Now

Scientific Publications

Healthcare Utilization Patterns Among Commercially Insured Patients with Prader-Willi Syndrome: A Retrospective Analysis of Administrative Claims

Prader-Willi syndrome (PWS) is a complex orphan endocrine disease characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality along with a significant burden on patients and caregivers. Life-long medical care is required but the consistency of services rendered to this population has not been evaluated. This study characterized use of US hospital care, specialty physician care, and growth hormone (GH) therapy for PWS patients at different life stages. Authors Merlin Butler, Ann Manzardo, Theresa…

Read Now

Scientific Publications

U.S. Prevalence & Mortality of Prader-Willi Syndrome: A Population-Based Study of Medical Claims

Prader-Willi syndrome (PWS) is a complex developmental genetic disorder associated with hypotonia, poor feeding in neonates, onset of hyperphagia in early childhood, and shorter overall life expectancy. Prior epidemiology studies of PWS have examined smaller populations, with limited research in a US population. The aim of this study was to provide a contemporary estimate of PWS prevalence and annual all-cause mortality in the US using a large administrative medical claims dataset. Authors Shawn McCandless, Marissa Suh, David Yin, Michael Yeh,…

Read Now

Scientific Publications

Comparative Comorbidity Burden Among Patients with Prader-Willi Syndrome: A Population-Level Cohort Survey

Prader-Willi syndrome (PWS) is a rare, complex multi-system genetic disorder characterized by hyperphagia and abnormal food-related behaviors that contribute to severe morbidity and early mortality and to a significant burden on patients and caregivers. The hyperphagia seen in people with PWS can result in significant obesity. This study assessed rates of comorbidities associated with obesity, including type II diabetes (T2D), cardiovascular disease (CVD), and sleep apnea (SA) in a large US PWS vs. a non-PWS cohort. Authors Diane Stafford, Justin…

Read Now

Scientific Publications

Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia

The purpose of this study was to systematically assess the prevalence, clinical consequences, and reporting of treatment-emergent hypophosphatemia within literature investigating IVI therapies marketed in the United States (US) Authors John Glaspy, Michelle Lim-Watson, Michael A Libre, Swagata Karkare, Nandini Hadker, Aleksandra Bajic-Lucas, William Strauss, Naomi Dahl Journal Therapeutics and Clinical Risk Management View publication…

Read Now

Scientific Publications

Evaluating the Ergonomic Outcomes of Digitally Assisted Vitreo-Retinal Surgery: A Systematic Literature Review

Recent developments in digitally assisted vitreo-retinal surgery (DAVS) and heads-up setup were introduced to the global ophthalmic surgical community to enhance visualization with digital signal amplification, higher resolution, and increased depth of field, while addressing some of the ergonomic challenges associated with conventional microscopes Authors Leighton Morris, William Wiley, Van Sandwick, Chiraag Lathia, Hang Cheng, Dina Abulon, Nandini Hadker, Kalin Hennegan Journal ISPOR EU 2020 View publication…

Read Now

Scientific Publications

Evaluating the Level of Endo-illumination Required during Digitally Assisted Vitreo-Retinal Surgery (DAVS): A Systematic Literature Review

While technological or procedural advances have resulted in low complication and re-operation rates, there are limitations of existing technologies — including but not limited to: surgical endo-illumination challenges, need for in-procedure adjustments, and additional information/support provided by other surgical devices — all of which can create challenges for surgeons during procedures Authors Leighton Morris, Alan Franklin, Van Sandwick, Chiraag Lathia, Hang Cheng, Nandini Hadker, Kalin Hennegan Journal ISPOR EU 2020 View publication…

Read Now

Blog

Is the Pricing Discount for Chinese NRDL Inclusion Worth it? NRDL Commercial Impact Assessment

Published July 6, 2021

Executive Summary The Chinese National Reimbursement Drug List (NRDL) is managed and negotiated by the National Healthcare Security Administration (NHSA) and drugs listed on the NRDL are reimbursed by the public insurance Since 2017, on average, a significant price discount of 44-61% was required for products to achieve a positive listing on the NRDL Based on average 2018 sales data, products included on the 2017 NRDL were able to achieve an increase in sales revenue (188%) despite the steep average…

Read Now

Blog

Poland’s Medical Fund Bill to Improve Access to Oncology Drugs

Published June 2, 2021

Executive Summary The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years The criteria for “innovativeness” that need to be met for inclusion on the list are still not fully fleshed out to date Only four of the 12 candidates on the list have been approved by the Health Minister to secure reimbursement…

Read Now

Blog

Novel Combinations: Double the Trouble

Published May 25, 2021

Executive Summary Branded novel combinations are increasingly entering the oncology market but bring a unique set of challenges to gain access and pricing success Dynamics beyond demonstrating synergistic efficacy should be taken into consideration to optimize combination price / access outcomes Trinity’s Take: In this article, Trinity uses select combination case studies to highlight the key elements to consider when thinking through price / access strategy for a novel combination Evaluation of the Novel Combinations Landscape The pursuit of a successful…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.